InvestSMART

ChemGenex Pharmaceuticals Ltd (ASX: CXS) - Announcements

DELISTED - Current share price for CXS : $0.700

ASX company news and announcements for ChemGenex Pharmaceuticals Ltd (CXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ChemGenex Pharmaceuticals Ltd (CXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ChemGenex Pharmaceuticals Ltd (CXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ChemGenex Pharmaceuticals Ltd (CXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Complete Response Letter from FDA Received 12 Apr 2010 9:17AM $0.470 $0.700 risen by 48.94%
- ODAC seeks validated diganostic before approval of OMAPRO 23 Mar 2010 10:10AM $0.440 $0.700 risen by 59.09%
- Half Yearly Report and Accounts 25 Feb 2010 10:21AM $0.690 $0.700 risen by 1.45%
- ODAC Postponed Due to Extreme Weather in Washington DC 9 Feb 2010 10:59AM $0.680 $0.700 risen by 2.94%
- Omapro ODAC meeting confirmed for 10 February 2010 17 Dec 2009 11:53AM $0.985 $0.700 fallen by 28.93%
- Omacetaxine European rights licensed to Hospira 14 Dec 2009 9:00AM $0.970 $0.700 fallen by 27.84%
- Updated omacetaxine data from multiTKI failure study 9 Dec 2009 10:13AM $0.950 $0.700 fallen by 26.32%
- Omapro Data Highlighted at ASH Press Conference 7 Dec 2009 9:03AM $0.970 $0.700 fallen by 27.84%
- EMEA validates ChemGenex`s MAA for omacetaxine 27 Nov 2009 9:41AM $0.940 $0.700 fallen by 25.53%
- US FDA accepts Omapro NDA - grants priority review 10 Nov 2009 9:20AM $0.880 $0.700 fallen by 20.45%
- Preliminary Final Report 27 Aug 2009 4:09PM $0.750 $0.700 fallen by 6.67%
- Omacetaxine Kills Leukemic Stem Cells in Human CML Models 9 Jun 2009 9:13AM $0.565 $0.700 risen by 23.89%
- Omacetaxine Shows Activity in Refractory CML 9 Jun 2009 9:11AM $0.565 $0.700 risen by 23.89%
- Omacetaxine Clinical Data Presented at ASCO 2 Jun 2009 8:25AM $0.565 $0.700 risen by 23.89%
- Rights Issue Fully Subscribed, Further $1 Million Placement 27 May 2009 9:56AM $0.530 $0.700 risen by 32.08%
- Information Booklet for Shareholders 21 Apr 2009 9:23AM $0.435 $0.700 risen by 60.92%
- Non-Renounceable Issue 21 Apr 2009 9:20AM $0.435 $0.700 risen by 60.92%
- Reinstatement to Official Quotation 9 Apr 2009 9:26AM $0.420 $0.700 risen by 66.67%
- Placement and Non-Renounceable Rights Issue 9 Apr 2009 9:26AM $0.420 $0.700 risen by 66.67%
- Suspension from Official Quotation 8 Apr 2009 9:19AM n/a $0.700 n/a
- Trading Halt 6 Apr 2009 9:43AM n/a $0.700 n/a
- New Data Suggests Omacetaxine Eradicates Leukemic Stem Cells 27 Mar 2009 9:27AM $0.590 $0.700 risen by 18.64%
- Half Yearly Report and Accounts 25 Feb 2009 5:59PM $0.335 $0.700 risen by 108.96%
- FDA Grants Orphan Drug Designation to Omacetaxine for MDS 20 Jan 2009 9:58AM $0.455 $0.700 risen by 53.85%
- Interim Clinical Trial Results Presented at ASH Conference 9 Dec 2008 9:03AM $0.470 $0.700 risen by 48.94%

26 - 50 of 105 results

Page 2 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.